Asia-Pacific Blood Screening Market, By Products and Services (Reagents and Kits, Instruments, Software and Services), Technology (Nucleic Acid Test, Enzyme-Linked Immunosorbent Assay, Rapid Tests, Western Blot Assay, Next-Generation Sequencing, Others), Disease Type (Respiratory Diseases, Diabetes Mellitus, Oncology, Cholesterol, HIV/AIDS, Cold and Flu, Infectious Diseases, Others), End User (Diagnostic Centers, Blood Bank, Hospitals, Clinics, Ambulatory Surgical Centers), Country (Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific)-Industry Trends and Forecast to 2029
Market Analysis and Insights Asia-Pacific Blood Screening Market
The blood screening market is expected to witness market growth at a rate of 7.99% in the forecast period of 2022 to 2029. Data Bridge Market Research report on blood screening market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The rise in the awareness amongst the patients regarding the donation of blood to a serious patient is escalating the growth of blood screening market.
Blood screening is basically referred to as a medical test that is carried out on blood samples for diagnosis of several diseases including hepatitis, syphilis, AIDS and other clinical conditions including pregnancy. Besides, it also assists in monitoring diseases and avoid health issues and a variability of other conditions including infections and cancer.
Major factors that are expected to boost the growth of the blood screening market in the forecast period are the rise in the prevalence of new form of pathogens. Furthermore, the increasing geriatric population is further anticipated to propel the growth of the blood screening market. Moreover, the growing levels of investment for the development of advanced technology is further estimated to cushion the growth of the blood screening market. On the other hand, the substitute technologies is further projected to impede the growth of the blood screening market in the timeline period.
In addition, the growing adoptions and acceptance rates from the consumers ever since the launch of instruments will further provide potential opportunities for the growth of the blood screening market in the coming years. However, the growing costs involved in sampling of blood which might further challenge the growth of the blood screening market in the near future.
This blood screening market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the blood screening market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you take an informed market decision to achieve market growth.
Asia-Pacific Blood Screening Market Scope and Market Size
The blood screening market is segmented on the basis of products and services, technology, disease type and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them in making strategic decisions for the identification of core market applications.
- On the basis of products and services, the blood screening market is segmented into reagents and kits, instruments and software and services. Reagents and kits are further sub-segmented into NAT reagents and kits, ELISA reagents and kits others as well. NAT reagents is further sub-segmented into enzymes and polymerases, standards and controls, probes and primers, buffers, nucleotides and solutions also labelling and detection reagents. ELISA reagents and kits is further sub-segmented into immunosorbents, controls, conjugates (antigen or antibody-conjugated enzyme), substrates (of enzymes) also sample diluents and wash solutions. Instruments segment is further segmented into instruments, product types and instruments and purchase type.
- On the basis of technology, the blood screening market is segmented into nucleic acid test, enzyme-linked immunosorbent assay (ELISA), rapid tests, western blot assay, next-generation sequencing (NGS) and others. Nucleic acid test is further sub-segmented into transcription-mediated amplification (TMA) and real-time polymerase chain reaction (PCR). Enzyme-linked immunosorbent assay (ELISA) is further segmented into ELISA market, by platform, ELISA market, by generation. ELISA market, by platform is further sub-segmented into chemiluminescence immunoassay (CLIA), fluorescence immunoassay (FIA) and colorimetric immunoassay (CI). ELISA market, by generation is further segmented into first-generation ELISA, second-generation ELISA, third-generation ELISA and fourth-generation and above.
- On the basis of disease type, the blood screening market is segmented into respiratory diseases, diabetes mellitus, oncology, cholesterol, HIV/AIDS, cold and flu, infectious diseases and others.
- On the basis of end user, the blood screening market is segmented into diagnostic centers, blood bank, hospitals, clinics and ambulatory surgical centers.
Blood Screening Market Country Level Analysis
The blood screening market is analyzed, and market size insights and trends are provided by country, products and services, technology, disease type and end user as referenced above.
The countries covered in the blood screening market report are the China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, and Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).
The country section of the blood screening market report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as consumption volumes, production sites, and volumes, import-export analysis, price trend analysis, cost of raw materials, downstream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The blood screening market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the blood screening market, the impact of technology using lifeline curves, and changes in healthcare regulatory scenarios and their impact on the blood screening market. The data is available for the historic period 2010-2020.
Competitive Landscape and Blood Screening Market Share Analysis
The blood screening market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to the blood screening market.
Some of the major players operating in the blood screening market are Enzo Biochem Inc., Meridian Life Science., BD, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, BioMérieux SA, Beckman Coulter, Inc., Abbott, F. Hoffmann-La Roche Ltd, Cepheid., Grifols, S.A., Siemens, Ortho Clinical Diagnostics, Immucor, Inc., and Hologic Inc., among others.
SKU-